Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

19.67USD
19 Oct 2018
Change (% chg)

$-0.29 (-1.45%)
Prev Close
$19.96
Open
$20.10
Day's High
$20.33
Day's Low
$19.38
Volume
122,822
Avg. Vol
269,577
52-wk High
$24.30
52-wk Low
$11.12

Chart for

About

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The... (more)

Overall

Beta: 3.11
Market Cap(Mil.): $444.74
Shares Outstanding(Mil.): 32.58
Dividend: --
Yield (%): --

Financials

  CARA.OQ Industry Sector
P/E (TTM): -- 85.68 33.65
EPS (TTM): -2.33 -- --
ROI: -66.80 0.45 14.28
ROE: -67.79 1.37 16.00

Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge

Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.

23 May 2018

BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement

* CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS

23 May 2018

BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus

* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 May 2018

BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.51

* CARA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

Earnings vs. Estimates